NCT00542022View on ClinicalTrials.gov

Efficacy, Tolerability and Safety Study in Rheumatoid Arthritis (0812-008)

PHASE2CompletedINTERVENTIONAL
Enrollment

149

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

May 31, 2005

Study Completion Date

May 31, 2005

Conditions
Arthritis, Rheumatoid
Interventions
DRUG

MK0812 / Duration of Treatment: 12 Weeks

DRUG

Comparator: placebo (unspecified) / Duration of Treatment: 12 Weeks

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00542022 - Efficacy, Tolerability and Safety Study in Rheumatoid Arthritis (0812-008) | Biotech Hunter | Biotech Hunter